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ABSTRACT
Introduction Progression to symptomatic Alzheimer 
disease (AD) occurs slowly over a series of preclinical 
stages. Declining functional mobility may be an early 
indicator of loss of brain network integration and may lead 
to an increased risk of experiencing falls. It is unknown 
whether measures of functional mobility and falls are 
preclinical markers of AD. The purpose of this study is to 
examine (1) the relationship between falls and functional 
mobility with AD biomarkers to determine when falls occur 
within the temporal progression to symptomatic Alzheimer 
disease, and (2) the attentional compared with perceptual/
motor systems that underlie falls and functional mobility 
changes seen with AD.
Methods and analysis This longitudinal cohort study will 
be conducted at the Knight Alzheimer Disease Research 
Center. Approximately 350 cognitively normal participants 
(with and without preclinical AD) will complete an in- 
home visit every year for 4 years. During each yearly 
assessment, functional mobility will be assessed using 
the Performance Oriented Mobility Assessment, Timed Up 
and Go, and Timed Up and Go dual task. Data regarding 
falls (including number and severity) will be collected 
monthly by self- report and confirmed through interviews. 
This study will leverage ongoing neuropsychological 
assessments and neuroimaging (including molecular 
imaging using positron emission tomography and MRI) 
performed by the Knight Alzheimer Disease Research 
Center. Relationships between falls and biomarkers of 
amyloid, tau and neurodegeneration will be evaluated.
Ethics and dissemination This study was approved 
by the Washington University in St. Louis Institutional 
Review Board (reference number 201807135). Written 
informed consent will be obtained in the home prior to the 
collection of any study data. Results will be published in 
peer- reviewed publications and presented at national and 
international conferences.
Trial registration number NCT04949529; Pre- results.
INTRODUCTION
Alzheimer disease (AD) is a slowly progres-
sive neurodegenerative disease that affects 
60%–70% of the over 50 million people living 
with dementia worldwide.1 2 Progression 
to symptomatic AD occurs slowly through 
a series of preclinical stages marked by 
changes in molecular biomarkers that can be 
quantified by neuroimaging, cerebrospinal 
fluid (CSF) or plasma measures.3 Cognitively 
normal (CN) stage 0 individuals have no 
biomarker abnormalities. CN stage 1 individ-
uals have only cerebral amyloidosis, CN stage 
2 individuals have amyloidosis and neurode-
generation, and CN stage 3 individuals have 
evidence of amyloidosis, neurodegenera-
tion and subtle cognitive changes.4–7 These 
preclinical stages of AD develop over decades 
and are considered clinically silent.3 However, 
emerging evidence suggests that impaired 
functional mobility (gait and balance) and 
subsequent falls8 may precede symptomatic 
cognitive impairment.3 9 Declining func-
tional mobility and increases in falls may be 
due to subtle changes in attention, executive, 
motor and sensory processing, and may be an 
early indicator of loss of integration between 
the central (CNS) and peripheral nervous 
systems (PNS).8 10–12
Falls are a leading cause of injury, long- 
term disability, premature institutionalisation 
and injury- related death in older individ-
uals.13 14 Individuals with symptomatic AD 
have a 60%–80% increased risk of falling, 
Strengths and limitations of this study
 ► This study is the first to examine whether changes 
in falls and functional mobility, in conjunction with 
concurrent brain network changes, can predict pro-
gression to Alzheimer disease (AD) in older adults.
 ► This longitudinal study design will enable us to 
measure falls and functional mobility over 4 years 
with a well- characterised cohort of 350 community- 
dwelling older adults who at baseline are cognitively 
normal (with and without preclinical AD).
 ► Participants receive a comprehensive in- home eval-
uation of their fall risks and functional mobility, the 
results of which are shared with each participant.
 ► Older adults may not be compliant with fall monitor-
ing over time.
 ► It may be difficult to differentiate falling from age- 
related phenotypes such as frailty.
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and those who fall are five times more likely to be insti-
tutionalised than similar individuals who do not fall.13 15 
A knowledge gap exists as to whether functional mobility 
and falls could serve as preclinical markers of AD.16
We previously demonstrated that falls occur at higher 
rates during the preclinical phase of AD, and the mech-
anisms that underlie the deterioration of cognitive func-
tion were associated with declines in gait and balance 
necessary for functional mobility.9 Functional connec-
tions in the brain, referred to as resting state functional 
connectivity (rs- fc), decrease in symptomatic AD.17 We 
observed a decrease in rs- fc for CN individuals with 
preclinical AD in the dorsal attention network (DAN), a 
set of brain regions involved in attentional control and 
planning.17 Functional connections both within the DAN 
and across other resting state networks (RSNs) may affect 
one’s functional mobility when attempting to navigate 
home and community environments. While self- reported 
performance is obtained from CN individuals (with and 
without preclinical AD), performance- based measures of 
everyday function are not recorded. Additional research 
is therefore needed to examine the relationship between 
functional mobility/falls and rs- fc, especially for CN indi-
viduals with preclinical AD.
For this longitudinal observational study, we will eval-
uate CN individuals (with and without preclinical AD) at 
baseline who are currently undergoing comprehensive 
clinical, neuropsychological and biomarker evaluations at 
the Knight Alzheimer Disease Research Center (Knight 
ADRC). Annually, we will conduct an in- home evaluation 
of fall risks and functional mobility and prospective ascer-
tainment of falls. Comparisons of objective assessments 
of functional mobility will be performed with regard to 
measures of brain pathology (using in vivo markers of 
cerebral amyloidosis and neurodegeneration) to allow 
us to characterise when changes in falls and functional 
mobility occur during the preclinical stages of AD. We 
will also examine attentional compared with perceptual/
motor systems that underlie falls and functional mobility 
in preclinical AD. Falls and functional mobility measures 
could serve as innovative, inexpensive screening tools to 
identify individuals at increased risk for progression to 
symptomatic AD. This may have important implications 
for the timing of interventions in secondary prevention 
trials in AD and for the development of more precise, 
effective treatments for individuals with AD.18
METHODS AND ANALYSIS
Participants
In this longitudinal cohort study, community- dwelling 
older adults will be recruited from an existing cohort 
followed by the Knight ADRC. Inclusion criteria for 
this study are as follows: ≥65 years of age, CN (Clin-
ical Dementia Rating (CDR)19 score of 0, indicating 
no dementia), and collection of biomarkers (CSF) 
and/or neuroimaging (positron emission tomography 
(PET) and/or MRI) within 2 years of study enrolment. 
Recruitment procedures for the Knight ADRC have been 
published previously.20
Recruitment
Participants (N=350) will be recruited for in- home visits 
near the time of their annual clinical assessment at the 
Knight ADRC. Knight ADRC staff will approach partic-
ipants who meet inclusion criteria about their interest 
regarding this study. If interested, potential participants 
will be referred to a study team member who will provide 
a detailed description of the study procedures and invite 
the individual to participate. Letters will also be sent to 
all eligible individuals to invite them to participate in 
this study. Written, informed consent will be obtained in 
the home prior to the collection of any study data. This 
study was approved by the Institutional Review Board at 
Washington University in St. Louis (reference number: 
201807135).
Study procedures
All Knight ADRC participants in principle complete 
longitudinal clinical and neuropsychological assessment 
and biomarker studies of biofluids (blood, CSF) and 
neuroimaging (amyloid PET, structural and functional 
MRI; see grey boxes in figure 1). For this study, partici-
pants additionally will receive an annual in- home visit and 
will report falls prospectively for the duration of the study 
(see blue boxes in figure 1).
Knight ADRC Clinical Assessment21
Knight ADRC participants complete an annual clinical 
assessment battery administered by an experienced clini-
cian using a standardised protocol. During this visit, the 
CDR assesses the participant’s cognitive and functional 
performance: 0=CN, 0.5=very mild symptomatic AD, 
1=mild symptomatic AD, 2=moderate symptomatic AD or 
3=severe symptomatic AD.19 A neurological examination 
is performed for each participant. At enrolment, partici-
pants must have a CDR=0.
Knight ADRC Psychometric/Neuropsychological Assessments22
Participants complete a standard 2- hour psychometric 
battery within 2 weeks of their annual clinical assessment 
by an experienced psychometrist and board- certified 
neurologist blinded to the participant’s preclinical AD 
status.22 A sensitive composite of attentional and exec-
utive control tests that is highly predictive of the transi-
tion from healthy ageing to symptomatic AD23–25 will be 
compared with functional mobility and fall measures.22
Biomarker acquisition/brain neuropathology assessments26
Participants also complete PET scans27 and MRI28 and 
undergo CSF and blood collection29 30 at the Knight 
ADRC every 3 years.
PET imaging
PET imaging will be conducted on a 3T Siemens Biograph 
mMR hybrid scanner using the radiotracer [18F] Flor-
betapir (AV45) to detect in vivo presence of amyloid in 
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the brain.27 Quantitative image analysis will be performed 
using a standard amyloid imaging analysis protocol26 
that uses FreeSurfer regions of interest (ROIs; Martinos 
Center for Biomedical Imaging, Charlestown, Massachu-
setts, USA). Regional standardised uptake value ratios 
(SUVRs) will be obtained using the cerebellum as the 
reference region.
Structural MRI
High- resolution structural MRI scans will be acquired 
using a T1- weighted magnetisation- prepared rapid 
gradient echo sequence to analyse brain volumetrics. 
Images will be subsequently analysed using standard 
procedures developed at the Knight ADRC using Free-
Surfer to delineate brain regions,31 including cortical and 
subcortical areas, typically affected by AD.28
Functional MRI/network dysfunction
During the MRI scan, rs- fc scans will be obtained using 
a gradient spin- echo sequence. Participants will be 
instructed to fixate on a visual crosshair and not to fall 
asleep. Rs- fc pre- processing and post- processing will be 
performed using standardised, in- house methods.32 In 
preparation for correlation analysis, data will be spatially 
smoothed with a 6 mm full- width at half maximum 
Gaussian blur. Then, temporal low- pass filtering (f<0.1 Hz) 
will be applied to the time series of each voxel. Finally, 
spurious variance will be removed using linear regres-
sion for (1) six parameters generated from head motion 
correction, (2) the whole brain signal and (3) signals 
from ventricular and cerebral white matter. An ROI- based 
analysis consisting of 298 seeds will be performed with a 
Pearson’s correlation coefficient computed between pair-
wise ROI time courses across all areas within RSNs. From 
these 298 seeds, correlation matrices will be generated 
for each participant. For the 13 RSNs, correlation coeffi-
cients across ROI pairs within a network will be averaged 
to form a composite score. Based on average matrices, 
both intra- network (diagonal) and inter- network (off 
diagonal) composite scores will be generated.
CSF biomarkers
CSF will be collected at approximately 08:00 following 
overnight fasting.33 About 20–30 mL of CSF is collected, 
centrifuged briefly at low speed, aliquoted into polypro-
pylene tubes and then stored at −80°C. Aβ40, Aβ42, total 
tau (tTau) and tau phosphorylated at 181 (pTau181) are 
measured by chemiluminescent enzyme immunoassay 
using a fully automated platform (LUMIPULSE G1200, 
Fujirebio)34 according to the manufacturer’s specifica-
tions. APOE genotype will be determined by genotyping 
rs7412 and rs429358 using Taqman genotyping tech-
nology as described previously.35
Preclinical AD staging
Biomarker positivity will be defined by correlating 
biomarker values at baseline with the risk of developing 
AD symptoms over time. The derivation of the biomarker 
cut- offs will be independent of the data collected in this 
project. Of note, CSF markers of tauopathy (pTau181) 
and neurodegeneration (tTau) are extremely highly 
correlated (r~0.96), so further stratification of stage by 
tauopathy would not be meaningful.36 Participants will be 
classified as follows: CN if measures of amyloid, neuro-
degeneration and episodic memory are normal; stage 1 
if only measures of amyloid are abnormal by CSF Aβ42/
Aβ40 or amyloid PET mean cortical SUVRs (which are 
highly concordant); stage 2 if only measures of amyloid 
and neurodegeneration (by CSF tTau) are abnormal; and 
stage 3 if measures of amyloid, neurodegeneration and 
episodic memory are abnormal.37
Annual in-home visit
An occupational therapist (OT), blinded to partici-
pants’ preclinical AD status, will complete a 120–180 min 
in- home visit annually for 4 years. The OT will conduct 
assessments related to the PNS as well as in- home func-
tional mobility and recognised fall covariates (tables 1 and 
2). Although the annual visit is typically completed in one 
session, it will be completed over two sessions if needed 
due to participant fatigue and/or request. Participants 
Figure 1 Research design overview. Measures of interest collected by the Knight Alzheimer Disease Research Center (Knight 
ADRC) will be available at no cost. In- home assessments will be collected annually, and falls will be monitored prospectively.
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Stroop colour naming task51* Colour naming of congruent (eg, red), neutral (eg, deep) or 
incongruent (eg, blue) word
Simon task52* Naming direction of an arrow with a keypress that is 
spatially consistent or inconsistent with the location of the 
arrow including congruent and incongruent positioning
Attentional switching task53* Switching every other trial between making odd- even 











30- second chair stand test55 A score below the norm will be considered indicative of 
decreased lower extremity strength and function
Handheld dynamometer56 Minimal change in the peak torque value for lower extremity 
strength will be measured
Grip strength Handheld dynamometer57 Pounds of force will be captured for grip strength
Vision Early Treatment Diabetic Retinopathy Study 
(ETDRS) test58
Visual acuity score; number of correct letters read
Pelli- Robson test59 Contrast sensitivity; letter- by- letter
Sensation Tuning fork, sharp60 8- Item questionnaire and sensation testing (vibration (feet) 





Performance- Oriented Mobility Assessment 
(POMA)61
A task- oriented assessment of 9 balance tasks and 7 items 
to assess gait
Gait speed Timed Up and Go (TUG) test62 Timed task of standing up, walking 3 m, turning, walking 
back and sitting down
Dual- task gait Timed Up and Go Cognitive (TUGcog)
63 TUG test while reciting serial 3s with subtractions from 
various points
Dual- task gait Timed Up and Go Manual (TUGman)
64 TUG test while carrying a glass of water
Additional 
assessments
Alcohol abuse Short Michigan Alcoholism Screening Test—
Geriatric Version (SMAST- G)65
10- Item interview
Depression Patient Health Questionnaire (PHQ-9)66 10- Item questionnaire to assess frequency of symptoms; 
0–27 points
Geriatric Depression Scale—Short Form 
(GDS- SF)67*
15- Item questionnaire; 0–15 points
Urinary incontinence Frequency and type68 Short questionnaire of frequency and type (stress, urge or 
other)
Pain Self- report69 Pain scale from 12- item Short Form Survey
Medication Medication review* Medications and dosages
Functional capacity Older Adults Resources and Services 
Activities of Daily Living (OARS ADL) scale70




Performance Assessment of Self- Care Skills 
(PASS)71
Evaluates independence, safety, and adequacy with 
shopping, chequebook balancing and medication 
management
Falls behaviour Falls Behavioural Scale for Older People 
(FaB)72
30- Item questionnaire; rated from 1 (least protective) to 4 
(most protective) behaviours to prevent falls
Self- efficacy Falls Efficacy
Scale—International (FES- ISF)73
7 daily activities; rated from 1 (not at all) to 4 (very 
concerned) about falling during specific activities
Home hazards Westmead Home Safety Assessment 
(WeSHA)74
Rates 72 environmental home hazards as hazard/no hazard
Olfaction University of Pennsylvania Smell 
Identification Test (UPSIT)75
40- Item smell identification test; 0–40 points
Hearing Hearing Handicap Inventory for the Elderly 
Screening Version (HHIE- S)76
10- Item questionnaire to screen for hearing impairment; 
0–40 points
Brief Hearing Test Screening tone test at varying frequencies
*Collected at the Knight ADRC.
Knight ADRC, Knight Alzheimer Disease Research Center.
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will receive a report with their results from the home visit 
and fall risk assessment based on established fall risk cut- 
off scores.38
Monthly fall reporting
Participants will report falls prospectively via automated 
call or email every month for 4 years using the gold stan-
dard for fall reporting, including daily calendar jour-
nals, fall interviews and monetary compensation for 
reporting.39 Participants will also receive a standardised 
fall report form to record the time and location of a fall, 
nature of the fall environment, specific activity at the time 
of the fall and any somatic complaints that proceeded 
the fall.40 If a participant reports a fall, an interviewer 
blinded to preclinical AD status will call the participant 
to complete a fall interview to verify the fall, defined as 
an unintentional movement to the floor, ground or an 
object below knee level. The interviewer will then gather 
additional information about any subsequent injuries or 
medical treatment.9 41 42 The rate (number) and severity 
(calculated with a standardised algorithm from medical 
records and participant report) of falls will be gener-
ated.13 The falls severity score will be quantified using a 
previously published algorithm: no falls (0), 1 fall without 
serious injury (1), any fall with minor injury or more than 
1 fall (2), and major injury requiring hospitalisation (3).14
Measures
An overview of the assessments collected at the Knight 
ADRC and annual in- home visits, including CNS and 
PNS measures, functional mobility, additional covariates 
of interest and fall covariates, for this study are listed in 
tables 1 and 2.
Statistical analysis plan
Data will be entered into Research Electronic Data 
Capture (REDCap),43 a secure, web- based application, 
and analysed using SAS, V.9.4 (SAS Institute). Differences 
in baseline characteristics across groups will be compared 
using appropriate statistics (χ2 test, Student’s t- test or 
Mann- Whitney U test). Composites and cut- offs will 
be calculated as described in the Methods and analysis 
section (see table 2). Models for analysing AD biomarkers 
and cognition will include age, gender, fall risk composite 
score, APOE status (at least APOE ε4 allele), as well as 
possible interactions among study variables. Models will 
be implemented using PROC GLM or PROC MIXED/
SAS.
Statistical analysis plan for the primary aim
We will examine the distributions of falls (number and 
severity) over a 1- year follow- up window and baseline 
functional mobility scores across the preclinical stages 
of AD (0, 1, 2 and 3),4 with appropriate transformations 
as needed. Falls severity scores across preclinical stages 
will be compared using analysis of covariance models.44 
Similar analyses will be conducted to compare each of 
the functional mobility measures across the preclinical 
stages of AD. We will implement adequate approaches 
(eg, Benjamini- Hochberg false discovery procedure)45 to 
control for the overall type I error rate due to multiple 
Table 2 Fall covariate composite score variables
Construct Measure Description Fall risk cut- off38
Vision Early Treatment Diabetic Retinopathy 
Study (ETDRS) test58
Visual acuity score; number of correct letters 
read
≤12
Pelli- Robson test59 Contrast sensitivity; letter- by- letter <36 letters
Alcohol abuse Short Michigan Alcoholism Screening 
Test—Geriatric Version (SMAST- G)65
10- Item interview ≥2
Depression Geriatric Depression Scale—Short Form 
(GDS- SF)67*
15- Item questionnaire; 0–15 points >4
Urinary incontinence Frequency and type68 Short questionnaire of frequency and type 
(stress, urge or other)
≥weekly urge 
incontinence
Pain Self- report69 Pain scale from 12- item Short Form Survey ≥moderate
Medication Medication review* Medications and dosages ≥4 medications
Functional capacity Older Adults Resources and Services 
Activities of Daily Living (OARS ADL) 
scale70
Ability to perform 14 activities; 0–2 scale, higher 
scores indicate greater independence
>4
Previous falls Previous falls38 Total falls in the past 12 months, self- report >0
Home hazards Westmead Home Safety Assessment 
(WeSHA)74
Rates 72 environmental home hazards as 
hazard/no hazard
≥4 hazards
Self- efficacy Falls Efficacy
Scale—International (FES- ISF)73
7 daily activities; rated from 1 (not at all) to 4 
(very concerned) about falling during specific 
activities
>10
*Collected at the Knight ADRC.
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outcome variables (number and severity of falls, func-
tional mobility) tested in this aim.
We will also jointly model the longitudinal falls severity 
score and the time- to- symptom onset of AD (defined 
as the first time a participant receives a CDR >0) using 
general linear mixed effects models.46 For modelling the 
risk of developing AD, we will use the semiparametric 
Cox proportional hazards model. To address the associ-
ation between change in falls and the risk of developing 
symptomatic AD, we will implement joint models.47 48
Statistical analysis plan for the secondary aim
We will test a hypothesised model of attentional 
compared with perceptual/motor systems underlying 
falls in preclinical AD using structural equation models 
(SEMs) on cross- sectional data.49 The structural model 
will include the estimation of path coefficients among 
various latent constructs including brain neuropa-
thology, network dysfunction, PNS abnormalities and 
falls. We will fit and compare various SEMs for their 




To examine the relationship between falls, functional 
mobility and AD, we will enrol 350 older adults from the 
Knight ADRC. Based on the distribution of CN partici-
pants across clinical stages in the existing Knight ADRC 
database, the proposed sample size will provide at least 
80% statistical power to detect an effect size as small as 
0.225 SD on the falls severity score between two adjacent 
participant groups. From the Knight ADRC database, we 
fitted a survival curve from baseline to the time that a 
CDR >0 was first rendered. We found an estimated CDR 
progression rate of 7.2% per year for individuals with 
a mean age of 75 at baseline and an expected attrition 
of approximately 15%. We estimate that approximately 
300 participants will be assessed annually throughout 
the study, and approximately 75 of these individuals will 
progress to CDR >0 after baseline. This will provide at 
least 80% statistical power to detect a onefold increase 
in the risk of developing symptomatic AD for individuals 
with an increased rate of falls over time compared with 
those with slow or no changes in falls over time. These 
power computations were based on a log rank test at the 
5% significance level and assumed an annual rate of 4.7% 
of CDR progression for individuals with slow changes in 
disability over time.
Secondary aim
We also tested non- zero path coefficients that link the 
latent constructs of network dysfunction with atten-
tional compared with perceptual/motor systems, and 
to impaired functional mobility and falls. The proposed 
sample provides at least 80% statistical power to detect 
each path coefficient.
Participants and public involvement
Participants and the public were not involved in the 
design, conduct, reporting or dissemination plans of our 
research.
Ethics and dissemination
This study was approved by the Washington University in 
St. Louis Institutional Review Board (reference number 
201807135). Written informed consent will be obtained 
in the home prior to the collection of any study data. 
Participants may withdraw from the study at any time. 
Results will be published in peer- reviewed publications 
and presented at national and international conferences.
DISCUSSION
Changes in functional mobility and an increase in falls 
may be an early indicator of preclinical AD.3 16 50 Under-
lying deviations in functional connectivity may assist in 
identifying brain RSNs that are affected and lead to falls.17 
Measures of everyday function are not currently included 
in the evaluation of CN individuals with preclinical AD. 
To examine these relationships, this study will assess the 
number and severity of falls, functional mobility (gait 
and balance), and changes in functional connections 
(rs- fc) within and across RSNs in a sample of community- 
dwelling older adults. This will allow us to characterise 
when changes in falls and functional mobility occur 
during the preclinical stages of AD as well as potential 
mechanisms.
The strengths of this study include access to a large, 
well- characterised cohort of community- dwelling older 
adults at the Knight ADRC who are enthusiastic about 
participating in studies. Another strength includes a 
comprehensive in- home evaluation of a participant’s 
fall risks and functional mobility and the ability to share 
results with each participant.
Although the strengths are promising, there are a 
few limitations to this study. First, older adults may not 
be compliant with fall monitoring over time. The OTs 
will call participants to obtain fall information if partic-
ipants do not want to complete the fall monitoring via 
automated call or email. Lastly, it may be difficult to 
differentiate falling from ageing- related phenotypes 
such as frailty. We will collect information on covariates, 
including comorbid conditions and other fall risk factors, 
test these relationships in individuals without preclinical 
AD and control for these covariates in statistical analyses.
This study is designed to examine the relationship 
between falls and functional mobility and underlying 
attentional compared with perceptual/motor systems 
in preclinical stages of AD. The findings will enhance 
our understanding of the systemic manifestations of 
AD and may identify falls as a previously unknown risk 
factor for developing preclinical AD. If successful, this 
study can potentially inform the timing of interven-
tions in secondary prevention trials in AD as well as the 
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development of more precise, effective treatments for 
individuals at risk for progression to symptomatic AD.18
Twitter Susan L Stark @PEPLaboratory
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